JP2020504741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504741A5 JP2020504741A5 JP2019534245A JP2019534245A JP2020504741A5 JP 2020504741 A5 JP2020504741 A5 JP 2020504741A5 JP 2019534245 A JP2019534245 A JP 2019534245A JP 2019534245 A JP2019534245 A JP 2019534245A JP 2020504741 A5 JP2020504741 A5 JP 2020504741A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- group
- substituted
- ulm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(*)N(*)C(C(*)NC(C(C)N)=O)=O Chemical compound CC(*)N(*)C(C(*)NC(C(C)N)=O)=O 0.000 description 48
- DERXELLTUOVDQH-UHFFFAOYSA-N CN(C1)CC1F Chemical compound CN(C1)CC1F DERXELLTUOVDQH-UHFFFAOYSA-N 0.000 description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N C1Cc2ccccc2C1 Chemical compound C1Cc2ccccc2C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- IXHFNEAFAWRVCF-UHFFFAOYSA-N CC(C)C(NC)=O Chemical compound CC(C)C(NC)=O IXHFNEAFAWRVCF-UHFFFAOYSA-N 0.000 description 2
- ZAMXVCJJAQXCBT-UHFFFAOYSA-N CN(CC1)CC1F Chemical compound CN(CC1)CC1F ZAMXVCJJAQXCBT-UHFFFAOYSA-N 0.000 description 2
- YNZOOJLMTULUQT-XNWIYYODSA-N CN(CCC1)C1C(C1)N(C)C[C@@H]1F Chemical compound CN(CCC1)C1C(C1)N(C)C[C@@H]1F YNZOOJLMTULUQT-XNWIYYODSA-N 0.000 description 2
- VDOLWAQYIDIFME-WHFBIAKZSA-N CN(C[C@@H]1O)C[C@@H]1F Chemical compound CN(C[C@@H]1O)C[C@@H]1F VDOLWAQYIDIFME-WHFBIAKZSA-N 0.000 description 2
- SHAHSPDXKLHDNO-NKVNRFPTSA-N C[C@H](C[C@H]1F)C1C1N(C)CCCC1 Chemical compound C[C@H](C[C@H]1F)C1C1N(C)CCCC1 SHAHSPDXKLHDNO-NKVNRFPTSA-N 0.000 description 2
- KDSAXEOLUPBMBT-UHFFFAOYSA-N C=[Br]c1cc(c(C(c(c(F)ccc2NS(CC(CO)O)(=O)=O)c2F)=O)c[nH]2)c2nc1 Chemical compound C=[Br]c1cc(c(C(c(c(F)ccc2NS(CC(CO)O)(=O)=O)c2F)=O)c[nH]2)c2nc1 KDSAXEOLUPBMBT-UHFFFAOYSA-N 0.000 description 1
- RCOAYXFWTLIZRE-UHFFFAOYSA-N CC(C)(C)OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2Br)CC1)=O Chemical compound CC(C)(C)OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2Br)CC1)=O RCOAYXFWTLIZRE-UHFFFAOYSA-N 0.000 description 1
- ZTAZUQNGWKMQMQ-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1Oc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1)=O Chemical compound CC(C)(C)OC(N(C1)CC1Oc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1)=O ZTAZUQNGWKMQMQ-UHFFFAOYSA-N 0.000 description 1
- AGHUJPNOYUMQSV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1ccncc1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1ccncc1)=O AGHUJPNOYUMQSV-UHFFFAOYSA-N 0.000 description 1
- HFJDGWPENBIHKK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1cccc2c1C1OC1N(C(CCC(N1)=O)C1=O)C2=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1cccc2c1C1OC1N(C(CCC(N1)=O)C1=O)C2=O)=O HFJDGWPENBIHKK-UHFFFAOYSA-N 0.000 description 1
- KARHZPCIVJWKRD-MUUNZHRXSA-N CC(C)(C)OC(N1CCN(CCOCCOc(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NCCN(CC4)C[C@@H]4F)c3F)=O)c[nH]3)c3nc2)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(CCOCCOc(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NCCN(CC4)C[C@@H]4F)c3F)=O)c[nH]3)c3nc2)CC1)=O KARHZPCIVJWKRD-MUUNZHRXSA-N 0.000 description 1
- VTKNFMYABFTAQP-ZFGGDYGUSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(CNC(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(CNC(OC(C)(C)C)=O)=O VTKNFMYABFTAQP-ZFGGDYGUSA-N 0.000 description 1
- MGFBAMQBZTVJRS-UJSFRCSHSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCCN(CC1)CCN1C(CC1)=CC=C1c1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCCN(CC1)CCN1C(CC1)=CC=C1c1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1)=O MGFBAMQBZTVJRS-UJSFRCSHSA-N 0.000 description 1
- SRGDAQPTGJKAMK-RUDCESOPSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCOc(cc1)ccc1-[n](cc1-c(cc2CC3)ccc2C3=O)nc1-c1ccncc1)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCOc(cc1)ccc1-[n](cc1-c(cc2CC3)ccc2C3=O)nc1-c1ccncc1)=O SRGDAQPTGJKAMK-RUDCESOPSA-N 0.000 description 1
- NEJPPXZUWGFBDL-HTCXSVJXSA-N CC(C)C(C(N(C[C@@H](C1)O)[C@@H]1C(N[C@@H](C)c(cc1)ccc1-c1cnc[o]1)=O)=O)c1cc(C)n[o]1 Chemical compound CC(C)C(C(N(C[C@@H](C1)O)[C@@H]1C(N[C@@H](C)c(cc1)ccc1-c1cnc[o]1)=O)=O)c1cc(C)n[o]1 NEJPPXZUWGFBDL-HTCXSVJXSA-N 0.000 description 1
- SXFWBOTXORQGJN-UHFFFAOYSA-N CC(C)CCC(NC)=O Chemical compound CC(C)CCC(NC)=O SXFWBOTXORQGJN-UHFFFAOYSA-N 0.000 description 1
- IYDMGGPKSVWQRT-XZWHSSHBSA-N CC(C)Oc(cc(cc1)OC)c1C(N([C@@H]1c(cc2)ccc2Cl)C(N(CC2)CCN2C(C)=O)=O)=N[C@H]1c(cc1)ccc1Cl Chemical compound CC(C)Oc(cc(cc1)OC)c1C(N([C@@H]1c(cc2)ccc2Cl)C(N(CC2)CCN2C(C)=O)=O)=N[C@H]1c(cc1)ccc1Cl IYDMGGPKSVWQRT-XZWHSSHBSA-N 0.000 description 1
- CWWBCISTWBLCMI-CGYACHGYSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)N(Cc1ccccc11)C1=O Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)N(Cc1ccccc11)C1=O CWWBCISTWBLCMI-CGYACHGYSA-N 0.000 description 1
- FEWHVHJXHQNNTR-LFRRGIFHSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1C1=C(C/[O]=C(\c2ccccc2C2)/N2[C@@H](C(C)C)C(N(C[C@@H](C2)O)C2(C)C(NCc(cc2)ccc2C2=C(C/[O]=C(\c3c(C4)cccc3)/N4[C@@H](C(C)C)C(N(C[C@@H](C3)O)C3(C)C(NCc(cc3)ccc3C3=C(C)NCS3)=O)=O)NCS2)=O)=O)NCS1)=O)=O)N(Cc1ccccc11)C1=O Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1C1=C(C/[O]=C(\c2ccccc2C2)/N2[C@@H](C(C)C)C(N(C[C@@H](C2)O)C2(C)C(NCc(cc2)ccc2C2=C(C/[O]=C(\c3c(C4)cccc3)/N4[C@@H](C(C)C)C(N(C[C@@H](C3)O)C3(C)C(NCc(cc3)ccc3C3=C(C)NCS3)=O)=O)NCS2)=O)=O)NCS1)=O)=O)N(Cc1ccccc11)C1=O FEWHVHJXHQNNTR-LFRRGIFHSA-N 0.000 description 1
- VBGCXCMUKOYHJF-RZUBCFFCSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1cc(C)n[s]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1cc(C)n[s]1 VBGCXCMUKOYHJF-RZUBCFFCSA-N 0.000 description 1
- YQOGFIVOLUHWKC-BAGYTPMASA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1n[nH]c(C)c1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1n[nH]c(C)c1 YQOGFIVOLUHWKC-BAGYTPMASA-N 0.000 description 1
- GFRBMXSURJKHGR-HSALFYBXSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nc(C)n[s]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nc(C)n[s]1 GFRBMXSURJKHGR-HSALFYBXSA-N 0.000 description 1
- IHDWHNABLZYBIH-CZHRTVMISA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[n]1Cc1c(-c2ccc(CNC([C@H](C[C@H](C3)O)N3C([C@H](C(C)C)c3nc(C)n[o]3)=O)=O)cc2)[s]cn1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[n]1Cc1c(-c2ccc(CNC([C@H](C[C@H](C3)O)N3C([C@H](C(C)C)c3nc(C)n[o]3)=O)=O)cc2)[s]cn1 IHDWHNABLZYBIH-CZHRTVMISA-N 0.000 description 1
- NMQOREDOOXJWIK-HSALFYBXSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[o]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[o]1 NMQOREDOOXJWIK-HSALFYBXSA-N 0.000 description 1
- UAOHBORKFLZBPO-HSALFYBXSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[s]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[s]1 UAOHBORKFLZBPO-HSALFYBXSA-N 0.000 description 1
- YYSFFVIJGUQALQ-BAGYTPMASA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1C1=C(C)NCS1)=O)=O)c1n[o]c(C)c1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1C1=C(C)NCS1)=O)=O)c1n[o]c(C)c1 YYSFFVIJGUQALQ-BAGYTPMASA-N 0.000 description 1
- GJGXQAODWZABIH-DMTNHVFBSA-N CC(C)[C@@H](CN(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=N)N(C=C1C2=CC=CC1)C2=O Chemical compound CC(C)[C@@H](CN(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=N)N(C=C1C2=CC=CC1)C2=O GJGXQAODWZABIH-DMTNHVFBSA-N 0.000 description 1
- YKABBFAFVRCVPP-AULYBMBSSA-N CC(CN(CC1)CCC1O[C@H](C1)C[C@@H]1NC)=O Chemical compound CC(CN(CC1)CCC1O[C@H](C1)C[C@@H]1NC)=O YKABBFAFVRCVPP-AULYBMBSSA-N 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N CC1CCNCC1 Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- GCEWJCVKPTZCRU-UHFFFAOYSA-N CCC1OC1NC Chemical compound CCC1OC1NC GCEWJCVKPTZCRU-UHFFFAOYSA-N 0.000 description 1
- QKGZBDBAWVAAKZ-UHFFFAOYSA-N CCCC(CCC)CCC(NC)=O Chemical compound CCCC(CCC)CCC(NC)=O QKGZBDBAWVAAKZ-UHFFFAOYSA-N 0.000 description 1
- QNEGXSQWCRRYSN-QPJOQSLLSA-N CCCS(Nc(c(F)c1-[n](cc2/C(/C=N)=C/N)c(cc3)c2nc3N(C)C2CCNCC2)ccc1F)(=O)=O Chemical compound CCCS(Nc(c(F)c1-[n](cc2/C(/C=N)=C/N)c(cc3)c2nc3N(C)C2CCNCC2)ccc1F)(=O)=O QNEGXSQWCRRYSN-QPJOQSLLSA-N 0.000 description 1
- JNSRQBZQGWFBKE-UHFFFAOYSA-N CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C(CC4)CCN4c4cccc5c4COCN(C(CCC(N4)=O)C4=O)C5=O)nc3c(-c3cncnc3)c2)c1F)(=O)=O Chemical compound CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C(CC4)CCN4c4cccc5c4COCN(C(CCC(N4)=O)C4=O)C5=O)nc3c(-c3cncnc3)c2)c1F)(=O)=O JNSRQBZQGWFBKE-UHFFFAOYSA-N 0.000 description 1
- DWLFNIVXWUHBJQ-UHFFFAOYSA-N CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C4CCNCC4)nc3c(-c3cncnc3)c2)c1F)(=O)=O Chemical compound CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C4CCNCC4)nc3c(-c3cncnc3)c2)c1F)(=O)=O DWLFNIVXWUHBJQ-UHFFFAOYSA-N 0.000 description 1
- QXMBWAUFPOAKNN-OQKACKPTSA-N CCCS(Nc(ccc(F)c1C(c(c2c3)c[nH]c2ncc3N(CC2)CCN2C(CCCC(N[C@@H](C(C)(C)C)C(N(C[C@@H](C2)O)[C@@H]2C(NCc(cc2)ccc2-c2c(C)nc[s]2)=O)=O)=O)=O)=O)c1F)(=O)=O Chemical compound CCCS(Nc(ccc(F)c1C(c(c2c3)c[nH]c2ncc3N(CC2)CCN2C(CCCC(N[C@@H](C(C)(C)C)C(N(C[C@@H](C2)O)[C@@H]2C(NCc(cc2)ccc2-c2c(C)nc[s]2)=O)=O)=O)=O)=O)c1F)(=O)=O QXMBWAUFPOAKNN-OQKACKPTSA-N 0.000 description 1
- RTRZHLJEMYASNC-HJZXASKDSA-N CN(C(CCC1N(C(c(cc2)c3cc2N(CC2)CCN2c(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4/C5=N/O)nc2-c2ccncc2)=O)C3=O)=O)C1=O Chemical compound CN(C(CCC1N(C(c(cc2)c3cc2N(CC2)CCN2c(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4/C5=N/O)nc2-c2ccncc2)=O)C3=O)=O)C1=O RTRZHLJEMYASNC-HJZXASKDSA-N 0.000 description 1
- KDUOPPMIWCFSEU-UHFFFAOYSA-N CN(C(CCC1N(C(c(cc2)c3cc2NCCNc(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4C5=O)nc2-c2ccncc2)=O)C3=O)=O)C1=O Chemical compound CN(C(CCC1N(C(c(cc2)c3cc2NCCNc(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4C5=O)nc2-c2ccncc2)=O)C3=O)=O)C1=O KDUOPPMIWCFSEU-UHFFFAOYSA-N 0.000 description 1
- VDOLWAQYIDIFME-UHFFFAOYSA-N CN(CC1O)CC1F Chemical compound CN(CC1O)CC1F VDOLWAQYIDIFME-UHFFFAOYSA-N 0.000 description 1
- LCQASUWGXZDLLK-FXLOMAGBSA-N CN(CCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2/C3=N/O)nc1-c1ccncc1)c(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound CN(CCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2/C3=N/O)nc1-c1ccncc1)c(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O LCQASUWGXZDLLK-FXLOMAGBSA-N 0.000 description 1
- VDOLWAQYIDIFME-BRJRFNKRSA-N CN(C[C@H]1O)CC1F Chemical compound CN(C[C@H]1O)CC1F VDOLWAQYIDIFME-BRJRFNKRSA-N 0.000 description 1
- LARRZJQWINEIFU-UHFFFAOYSA-N CN1CC(CCN2CCNCC2)CC1 Chemical compound CN1CC(CCN2CCNCC2)CC1 LARRZJQWINEIFU-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- UPIHZCDTQBTGHI-UHFFFAOYSA-N CNCCOc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1 Chemical compound CNCCOc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1 UPIHZCDTQBTGHI-UHFFFAOYSA-N 0.000 description 1
- DYGHSFRVQSBDJP-RXMQYKEDSA-N CS(N(CC1)C[C@@H]1F)(=O)=O Chemical compound CS(N(CC1)C[C@@H]1F)(=O)=O DYGHSFRVQSBDJP-RXMQYKEDSA-N 0.000 description 1
- UATHGXSVZBAWEK-JFHPQLLQSA-N C[C@@H](C(N[C@@H](C)C(N(C1)[C@H](CN(CCc2ccccc2)C2)[C@H]2[C@@H]1OCCO[C@H](C1)C(CN(CCC2=CCCC=C2)C2)[C@@H]2N1C([C@H](COC(CCC(OC)=O)=O)NC([C@H](N)NC)=O)=O)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C)C(N(C1)[C@H](CN(CCc2ccccc2)C2)[C@H]2[C@@H]1OCCO[C@H](C1)C(CN(CCC2=CCCC=C2)C2)[C@@H]2N1C([C@H](COC(CCC(OC)=O)=O)NC([C@H](N)NC)=O)=O)=O)=O)NC UATHGXSVZBAWEK-JFHPQLLQSA-N 0.000 description 1
- IBBHIZXRMBKKII-IYNDAXALSA-N C[C@@H](C(N[C@@H](C1CCCCC1)C(N(CC[C@@H]1C)[C@@H]1C(Nc1cc(C)n[n]1-c1ccccc1)=O)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C1CCCCC1)C(N(CC[C@@H]1C)[C@@H]1C(Nc1cc(C)n[n]1-c1ccccc1)=O)=O)=O)NC IBBHIZXRMBKKII-IYNDAXALSA-N 0.000 description 1
- AADMRSQDLRYQQU-UHFFFAOYSA-N Cc1cc(CCCCCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCCCCCN2CCN(C)CC2)n[o]1 AADMRSQDLRYQQU-UHFFFAOYSA-N 0.000 description 1
- NKJLAVFMTFUYGP-UHFFFAOYSA-N Cc1cc(CCCCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCCCCN2CCN(C)CC2)n[o]1 NKJLAVFMTFUYGP-UHFFFAOYSA-N 0.000 description 1
- PXRKWVGPKRKKFP-UHFFFAOYSA-N Cc1cc(CCCOCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCCOCCN2CCN(C)CC2)n[o]1 PXRKWVGPKRKKFP-UHFFFAOYSA-N 0.000 description 1
- CCGOLKRCFVKMCO-UHFFFAOYSA-N Cc1cc(CCOCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCOCCN2CCN(C)CC2)n[o]1 CCGOLKRCFVKMCO-UHFFFAOYSA-N 0.000 description 1
- BOECVYQYFLWQNP-UHFFFAOYSA-N Cc1cc(COCCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(COCCCN2CCN(C)CC2)n[o]1 BOECVYQYFLWQNP-UHFFFAOYSA-N 0.000 description 1
- OFOLFJNDUSEUPT-UHFFFAOYSA-N Cc1cc(COCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(COCCN2CCN(C)CC2)n[o]1 OFOLFJNDUSEUPT-UHFFFAOYSA-N 0.000 description 1
- LTCXOHTXCPOVIV-UMSPYCQHSA-N Cc1cc(O[C@H](C2)C[C@@H]2NC)ccc1 Chemical compound Cc1cc(O[C@H](C2)C[C@@H]2NC)ccc1 LTCXOHTXCPOVIV-UMSPYCQHSA-N 0.000 description 1
- QEBVSEQGCUZGCV-SECBINFHSA-N Nc1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 Chemical compound Nc1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 QEBVSEQGCUZGCV-SECBINFHSA-N 0.000 description 1
- UQPSXJLSPRHBBA-OQWWRJADSA-N O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCCOc3cccc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 Chemical compound O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCCOc3cccc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 UQPSXJLSPRHBBA-OQWWRJADSA-N 0.000 description 1
- CFJMFGGNHCSIHD-VRPJDWIJSA-N O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCOCCOc(cc3)cc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 Chemical compound O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCOCCOc(cc3)cc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 CFJMFGGNHCSIHD-VRPJDWIJSA-N 0.000 description 1
- RQPANKYMENZMFC-PHVLXYFRSA-N O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCCCOc2cc(-c(cccc3C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)ccc2)nc1-c1ccncc1 Chemical compound O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCCCOc2cc(-c(cccc3C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)ccc2)nc1-c1ccncc1 RQPANKYMENZMFC-PHVLXYFRSA-N 0.000 description 1
- KGZUGSKPAMJRRC-UHFFFAOYSA-N O=C(CC1)c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCc(cccc2)c2OCCOCCCOc(cccc2C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)nc1-c1ccncc1 Chemical compound O=C(CC1)c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCc(cccc2)c2OCCOCCCOc(cccc2C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)nc1-c1ccncc1 KGZUGSKPAMJRRC-UHFFFAOYSA-N 0.000 description 1
- DXQDVHBZWPXJPA-UHFFFAOYSA-N O=C(c(cc1)c2cc1N(C1)CC1N(C1)CC1Oc(cc1)ccc1-[n]1nc(C3C=CN=CC3)c(Br)c1)N(C(CCC(N1)=O)C1=O)C2=O Chemical compound O=C(c(cc1)c2cc1N(C1)CC1N(C1)CC1Oc(cc1)ccc1-[n]1nc(C3C=CN=CC3)c(Br)c1)N(C(CCC(N1)=O)C1=O)C2=O DXQDVHBZWPXJPA-UHFFFAOYSA-N 0.000 description 1
- CCERGJGFOODHOI-NDEPHWFRSA-N O=C(c1c2c(OCCCCN(CC3)CCN3c(cc3)ccc3-[n](cc3Br)nc3-c3ccncc3)ccc1)N([C@@H](CCC(N1)=O)C1=O)C2=O Chemical compound O=C(c1c2c(OCCCCN(CC3)CCN3c(cc3)ccc3-[n](cc3Br)nc3-c3ccncc3)ccc1)N([C@@H](CCC(N1)=O)C1=O)C2=O CCERGJGFOODHOI-NDEPHWFRSA-N 0.000 description 1
- UTSZNJIEZABRKU-OAQYLSRUSA-N O=CCN(CC1)CCN1c(cc1)ccc1-c1cc(c(C(c(c(F)c(cc2)NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 Chemical compound O=CCN(CC1)CCN1c(cc1)ccc1-c1cc(c(C(c(c(F)c(cc2)NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 UTSZNJIEZABRKU-OAQYLSRUSA-N 0.000 description 1
- RFWLATFOOGPHAS-AREMUKBSSA-N OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NS(N(CC4)C[C@@H]4F)(=O)=O)c3F)=O)c[nH]3)c3nc2)CC1)=O Chemical compound OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NS(N(CC4)C[C@@H]4F)(=O)=O)c3F)=O)c[nH]3)c3nc2)CC1)=O RFWLATFOOGPHAS-AREMUKBSSA-N 0.000 description 1
- SJCTVMPUXINNPA-UHFFFAOYSA-N OC(c(cc1)c2cc1N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc3)cc(CC4)c3C4=O)nc1-c1ccncc1)N(C(CCC(N1)=O)C1=O)C2=O Chemical compound OC(c(cc1)c2cc1N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc3)cc(CC4)c3C4=O)nc1-c1ccncc1)N(C(CCC(N1)=O)C1=O)C2=O SJCTVMPUXINNPA-UHFFFAOYSA-N 0.000 description 1
- YEFDWSQVRHOJFI-UHFFFAOYSA-N OCCCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1csncc1 Chemical compound OCCCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1csncc1 YEFDWSQVRHOJFI-UHFFFAOYSA-N 0.000 description 1
- PKXOFPCXFBCGEA-MECOZAJYSA-N OCCOc1cccc2c1C1OC1N([C@@H](CCC(N1)=O)C1=O)C2=O Chemical compound OCCOc1cccc2c1C1OC1N([C@@H](CCC(N1)=O)C1=O)C2=O PKXOFPCXFBCGEA-MECOZAJYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
Images
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023015526A JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2024180795A JP2025016525A (ja) | 2016-12-23 | 2024-10-16 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438803P | 2016-12-23 | 2016-12-23 | |
| US62/438,803 | 2016-12-23 | ||
| US201762582698P | 2017-11-07 | 2017-11-07 | |
| US62/582,698 | 2017-11-07 | ||
| PCT/US2017/068322 WO2018119448A1 (en) | 2016-12-23 | 2017-12-22 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015526A Division JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504741A JP2020504741A (ja) | 2020-02-13 |
| JP2020504741A5 true JP2020504741A5 (https=) | 2021-02-04 |
| JP7679173B2 JP7679173B2 (ja) | 2025-05-19 |
Family
ID=62625473
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534245A Active JP7679173B2 (ja) | 2016-12-23 | 2017-12-22 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2023015526A Pending JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2024180795A Pending JP2025016525A (ja) | 2016-12-23 | 2024-10-16 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015526A Pending JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2024180795A Pending JP2025016525A (ja) | 2016-12-23 | 2024-10-16 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10723717B2 (https=) |
| EP (1) | EP3558994A4 (https=) |
| JP (3) | JP7679173B2 (https=) |
| KR (3) | KR102564201B1 (https=) |
| CN (2) | CN117510491A (https=) |
| AU (2) | AU2017382436C1 (https=) |
| BR (1) | BR112019012878A2 (https=) |
| CA (1) | CA3047784A1 (https=) |
| CO (1) | CO2019007894A2 (https=) |
| IL (4) | IL325835A (https=) |
| MX (2) | MX2019007649A (https=) |
| WO (1) | WO2018119448A1 (https=) |
Families Citing this family (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2767532B1 (en) | 2012-12-21 | 2016-07-13 | National Institutes for Quantum and Radiological Science and Technology | Novel compound for imaging tau protein accumulated in the brain |
| AU2014364589B2 (en) | 2013-12-18 | 2020-02-27 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017011371A1 (en) | 2015-07-10 | 2017-01-19 | Arvinas, Inc | Mdm2-based modulators of proteolysis and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| WO2018053354A1 (en) | 2016-09-15 | 2018-03-22 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| IL290809B2 (en) | 2016-11-01 | 2024-01-01 | Arvinas Operations Inc | Tau-protein targeting protacs and associated methods of use |
| KR102674902B1 (ko) | 2016-12-01 | 2024-06-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| CN117510491A (zh) | 2016-12-23 | 2024-02-06 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法 |
| MX2019007646A (es) | 2016-12-23 | 2019-09-06 | Arvinas Operations Inc | Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso. |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| AU2018211975B2 (en) | 2017-01-26 | 2022-05-26 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| BR112019015484A2 (pt) | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
| US10787443B2 (en) * | 2017-04-28 | 2020-09-29 | Zamboni Chem Solutions Inc. | RAF-degrading conjugate compounds |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| CN118206529A (zh) | 2017-09-04 | 2024-06-18 | C4医药公司 | 二氢苯并咪唑酮 |
| CN111278816B (zh) | 2017-09-04 | 2024-03-15 | C4医药公司 | 二氢喹啉酮 |
| WO2019094772A1 (en) | 2017-11-10 | 2019-05-16 | The Regents Of The University Of Michigan | Ash1l degraders and methods of treatment therewith |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| US11220515B2 (en) | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
| JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー４ セラピューティクス， インコーポレイテッド | Ｉｋａｒｏｓの分解のためのセレブロン結合剤 |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| CN110357889B (zh) * | 2018-04-09 | 2022-03-15 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
| CA3095912A1 (en) * | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN119751456A (zh) | 2018-04-16 | 2025-04-04 | C4医药公司 | 螺环化合物 |
| JP7293343B2 (ja) | 2018-05-09 | 2023-06-19 | アプリノイア セラピューティクス リミテッド | ヘテロアリール化合物及びその使用 |
| WO2019222272A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| DK3820573T3 (da) | 2018-07-10 | 2023-10-23 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020027225A1 (ja) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| EP3841100A1 (en) | 2018-08-20 | 2021-06-30 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| MX2021001957A (es) | 2018-08-22 | 2021-07-15 | Cullgen Shanghai Inc | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| KR102642203B1 (ko) * | 2018-09-07 | 2024-03-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법 |
| KR102672549B1 (ko) * | 2018-09-30 | 2024-06-10 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 이소인돌린계 화합물, 이의 제조 방법, 약학 조성물 및 용도 |
| EP3864030A4 (en) * | 2018-10-12 | 2022-09-21 | The Scripps Research Institute | Compounds and methods for dcaf-mediated protein degradation |
| EP3891128A4 (en) * | 2018-12-05 | 2022-08-17 | Vividion Therapeutics, Inc. | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEOSUBSTRATE RECRUITMENT |
| EP3896062A4 (en) * | 2018-12-06 | 2022-06-15 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | ISOINDOLINE COMPOUND, METHOD FOR PREPARATION, PHARMACEUTICAL COMPOSITION AND USE OF ISOINDOLINE COMPOUND |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2020162725A1 (ko) * | 2019-02-07 | 2020-08-13 | 한국화학연구원 | 표적 단백질 ｅｅｄ 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 ｅｅｄ, ｅｚｈ2, 또는 ｐｒｃ2 관련 질환의 예방 또는 치료용 약학적 조성물 |
| EP3932922A4 (en) | 2019-02-25 | 2022-05-11 | ShanghaiTech University | SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE |
| JP7619952B2 (ja) * | 2019-02-25 | 2025-01-22 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | 変異型ハンチンチンタンパク質を標的とするための化合物及びその使用 |
| WO2020176983A1 (en) * | 2019-03-01 | 2020-09-10 | Ontario Institute For Cancer Research (Oicr) | Amide-based proteolysis modulators of b-rapidly accelerated fibrosarcoma (braf) and associated uses |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| CN120172958A (zh) | 2019-04-12 | 2025-06-20 | C4医药公司 | Ikaros和aiolos的三环降解物 |
| US12414995B2 (en) | 2019-04-16 | 2025-09-16 | Northwestern University | Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer |
| CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
| TWI762939B (zh) * | 2019-05-31 | 2022-05-01 | 大陸商海思科醫藥集團股份有限公司 | Btk抑制劑環衍生物及其製備方法和藥學上的應用 |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| CN119954801A (zh) | 2019-07-17 | 2025-05-09 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| WO2021016521A1 (en) * | 2019-07-25 | 2021-01-28 | Beth Israel Deaconess Medical Center, Inc. | Photo induced control of protein destruction |
| JP2021024787A (ja) | 2019-07-31 | 2021-02-22 | ファイメクス株式会社 | 複素環化合物 |
| WO2021020585A1 (ja) | 2019-07-31 | 2021-02-04 | ファイメクス株式会社 | 複素環化合物 |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| IL320609A (en) | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| WO2021061644A1 (en) * | 2019-09-23 | 2021-04-01 | Accutar Biotechnology Inc. | Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof |
| US10836749B1 (en) * | 2019-09-23 | 2020-11-17 | Accutar Biotechnology Inc. | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof |
| JP2022549222A (ja) * | 2019-09-23 | 2022-11-24 | アキュター バイオテクノロジー インコーポレイテッド | アンドロゲン受容体分解活性を有する新規尿素およびその使用 |
| CN115397821B (zh) | 2019-10-17 | 2024-09-03 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| WO2021097046A1 (en) | 2019-11-13 | 2021-05-20 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CA3161455A1 (en) * | 2019-11-13 | 2021-05-20 | Aprinoia Therapeutics Limited | Compounds for degrading tau protein aggregates and uses thereof |
| AU2020387392B2 (en) | 2019-11-19 | 2025-09-11 | Bristol-Myers Squibb Company | Compounds useful as inhibitors of Helios protein |
| AU2020397917A1 (en) | 2019-12-04 | 2022-06-23 | The Scripps Research Institute | GLP2 receptor agonists and methods of use |
| CN110950877B (zh) * | 2019-12-11 | 2022-06-28 | 齐鲁工业大学 | 一种双检测荧光探针、制备方法及其在检测硫化氢和铜离子中的应用 |
| JP2023507590A (ja) * | 2019-12-17 | 2023-02-24 | オリオニス バイオサイエンシズ，インコーポレイテッド | タンパク質の動員および／または分解を調節する化合物 |
| JP2023508891A (ja) * | 2019-12-17 | 2023-03-06 | オリオニス バイオサイエンシズ，インコーポレイテッド | タンパク質の動員および／または分解のための二機能性剤 |
| JP7682181B2 (ja) | 2019-12-18 | 2025-05-23 | ノバルティス アーゲー | ３－（５－メトキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| CA3165168A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| BR112022011827A2 (pt) | 2019-12-20 | 2022-08-30 | C4 Therapeutics Inc | Composto, composição farmacêutica, uso de um composto, métodos para tratamento ou profilaxia de câncer e para tratar um paciente com um distúrbio mediado por receptor do fator de crescimento epidérmico, e, invenção |
| KR20260017503A (ko) | 2020-02-14 | 2026-02-05 | 길리애드 사이언시즈, 인코포레이티드 | Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도 |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| CA3173262A1 (en) | 2020-02-26 | 2021-09-02 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
| AU2021231898A1 (en) | 2020-03-05 | 2022-10-27 | C4 Therapeutics, Inc. | Compounds for targeted degradation of BRD9 |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| US20220370416A1 (en) * | 2020-04-06 | 2022-11-24 | Arvinas Operations, Inc. | Compounds and methods for targeted degradation of kras |
| MX2022015732A (es) | 2020-06-09 | 2023-02-13 | Prelude Therapeutics Inc | Compuestos dirigidos a brm y métodos asociados de uso. |
| JP2023530937A (ja) * | 2020-06-17 | 2023-07-20 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | Ｅ３－リガーゼ系の共動員を介した標的化された異常なα－シヌクレイン種ならびに誘導されたユビキチン化およびプロテアソームクリアランス |
| WO2021255212A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Braf degraders |
| WO2021255213A1 (en) * | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Heterobifunctional compounds as degraders of braf |
| KR102559329B1 (ko) * | 2020-07-02 | 2023-07-25 | 포항공과대학교 산학협력단 | 신규한 프로탁 키메라 화합물, 이를 포함하는 표적 단백질 분해를 통한 질환의 예방, 개선 또는 치료용 약학적 조성물 |
| WO2022019597A1 (ko) | 2020-07-21 | 2022-01-27 | 주식회사 유빅스테라퓨틱스 | 안드로겐 수용체 분해용 화합물 및 이들의 의약 용도 |
| EP4192458A4 (en) | 2020-08-05 | 2024-09-04 | C4 Therapeutics, Inc. | COMPOUNDS FOR TARGETED DEGRADATION OF RET |
| AU2021321415A1 (en) * | 2020-08-07 | 2023-02-09 | Cornell University | Therapeutic composition of cure-pro compounds for targeted degradation of bet domain proteins, and methods of making and usage |
| JP2023536657A (ja) * | 2020-08-07 | 2023-08-28 | コーネル ユニバーシティー | タンパク質をｅ３リガーゼの媒介によって分解するための、治療上有用なｃｕｒｅ－ｐｒｏ分子、ならびにその作製方法及び使用方法 |
| JP7834721B2 (ja) * | 2020-08-28 | 2026-03-24 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| CN117062814A (zh) * | 2020-08-28 | 2023-11-14 | 阿维纳斯运营公司 | 快速加速纤维肉瘤蛋白降解的化合物和相关使用方法 |
| AR123492A1 (es) | 2020-09-14 | 2022-12-07 | Arvinas Operations Inc | Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno |
| WO2022066835A1 (en) | 2020-09-23 | 2022-03-31 | St. Jude Children's Research Hospital, Inc. | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| KR102532692B1 (ko) * | 2021-03-15 | 2023-05-16 | (주)피알지에스앤텍 | 신경섬유종증 2형 증후군 예방 또는 치료용 조성물 |
| KR20230160299A (ko) | 2021-03-23 | 2023-11-23 | 누베이션 바이오 인크. | 항암 핵 호르몬 수용체 표적화 화합물 |
| BR112023020077A2 (pt) | 2021-04-06 | 2023-11-14 | Bristol Myers Squibb Co | Compostos de oxoisoindolina substituída por piridinila |
| CN117279910A (zh) | 2021-04-16 | 2023-12-22 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| US12006314B2 (en) | 2021-05-03 | 2024-06-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| KR20240017814A (ko) | 2021-05-05 | 2024-02-08 | 바이오젠 엠에이 인코포레이티드 | 브루톤 티로신 키나제의 분해를 표적으로 하는 화합물 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| WO2022255888A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| PY2243958A (es) | 2021-06-03 | 2023-01-20 | Novartis Ag | Derivados de 3–(5–oxi)–1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos |
| WO2022261627A1 (en) * | 2021-06-07 | 2022-12-15 | The General Hospital Corporation | Inhibitors of ttbk1 |
| WO2022261250A1 (en) | 2021-06-08 | 2022-12-15 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| MX2023014771A (es) | 2021-06-09 | 2024-03-19 | Scripps Research Inst | Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso. |
| KR20240035526A (ko) | 2021-07-07 | 2024-03-15 | 바이오젠 엠에이 인코포레이티드 | Irak4 단백질의 분해를 표적하는 화합물 |
| WO2023283372A1 (en) | 2021-07-07 | 2023-01-12 | Biogen Ma Inc. | Compounds for targeting degradation of irak4 proteins |
| WO2023023941A1 (en) * | 2021-08-24 | 2023-03-02 | Biofront Ltd (Cayman) | Hpk1 degraders, compositions comprising the hpki degrader, and methods of using the same |
| WO2023034411A1 (en) | 2021-09-01 | 2023-03-09 | Oerth Bio Llc | Compositions and methods for targeted degradation of proteins in a plant cell |
| AU2022370021B2 (en) * | 2021-10-22 | 2026-04-16 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| CN115894450B (zh) * | 2021-11-30 | 2023-09-12 | 山东如至生物医药科技有限公司 | 一种新型多环类化合物及其组合物和用途 |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| EP4452415B1 (en) | 2021-12-22 | 2026-02-25 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| CN118574822A (zh) * | 2022-01-28 | 2024-08-30 | 甘李药业股份有限公司 | 新型protac化合物 |
| CA3253296A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Zinc Finger Degradation Agents of the Ikaros Family and Their Uses |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| JP2025523393A (ja) | 2022-06-06 | 2025-07-23 | シーフォー セラピューティクス， インコーポレイテッド | 二環式置換グルタルイミドセレブロンバインダー |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024050016A1 (en) | 2022-08-31 | 2024-03-07 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024140638A1 (zh) * | 2022-12-27 | 2024-07-04 | 标新生物医药科技(上海)有限公司 | 基于硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用 |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| CN120882725A (zh) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | Kras调节化合物 |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
| US20250042922A1 (en) | 2023-06-30 | 2025-02-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| AU2024307234A1 (en) | 2023-06-30 | 2026-01-29 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| AU2024337913A1 (en) | 2023-09-08 | 2026-03-26 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096855A1 (en) | 2023-11-02 | 2025-05-08 | Kumquat Biosciences Inc. | Degraders and uses thereof |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137500A1 (en) | 2023-12-21 | 2025-06-26 | Dana-Farber Cancer Institute, Inc. | Kinase inhibition and degradation |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025235298A1 (en) * | 2024-05-07 | 2025-11-13 | Nikang Therapeutics, Inc. | Bifunctional compounds containing thiazolyl derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026039365A1 (en) | 2024-08-12 | 2026-02-19 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121735910A (zh) * | 2024-09-27 | 2026-03-27 | 上海交通大学 | 一种模块化的分子胶化合物库及其构建方法和应用 |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ333903A (en) | 1996-07-24 | 2000-02-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1oxoisoindolines and method of reducing TNF-alpha levels in a mammal |
| CA2287387C (en) | 1997-05-14 | 2010-02-16 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for destruction of selected proteins |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| US6333344B1 (en) | 1999-05-05 | 2001-12-25 | Merck & Co. | Prolines as antimicrobial agents |
| US7041298B2 (en) | 2000-09-08 | 2006-05-09 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| CA2432932A1 (en) | 2001-02-16 | 2002-08-29 | Mark A. Scialdone | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| HN2002000136A (es) | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
| US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| WO2004005248A1 (en) | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| US7915293B2 (en) | 2003-05-30 | 2011-03-29 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| US7932382B2 (en) | 2004-01-16 | 2011-04-26 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| WO2005094818A1 (en) | 2004-03-23 | 2005-10-13 | Genentech, Inc. | Azabicyclo-octane inhibitors of iap |
| RS52545B (sr) | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
| BRPI0511350A (pt) | 2004-07-02 | 2007-12-04 | Genentech Inc | composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto |
| MX2007007195A (es) | 2004-12-20 | 2007-10-08 | Genentech Inc | Inhibidores de pirrolidina de iap. |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| ES2456671T3 (es) | 2005-02-25 | 2014-04-23 | Tetralogic Pharmaceuticals Corporation | Inhibidores diméricos de IAP |
| CN100383139C (zh) | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物 |
| WO2006113942A2 (en) | 2005-04-20 | 2006-10-26 | Schering Corporation | Method of inhibiting cathepsin activity |
| CN102206216B (zh) | 2005-06-22 | 2014-11-12 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
| KR20080042158A (ko) | 2005-08-31 | 2008-05-14 | 셀진 코포레이션 | 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법 |
| BRPI0708524A2 (pt) | 2006-03-03 | 2011-05-31 | Novartis Ag | compostos de n-formil hidroxilamina |
| WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| JP5230610B2 (ja) | 2006-05-05 | 2013-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 二価ｓｍａｃ模倣物およびその使用 |
| JP2009544620A (ja) | 2006-07-20 | 2009-12-17 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 自己免疫疾患及び炎症のためのプロリン尿素ｃｃｒ１アンタゴニスト |
| US20100056495A1 (en) | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| RU2448101C2 (ru) | 2006-08-30 | 2012-04-20 | Селджин Корпорейшн | 5-замещенные изоиндолиновые соединения |
| MX2009001989A (es) | 2006-08-30 | 2009-03-09 | Celgene Corp | Compuestos de isoindolina 5-substituidos. |
| CA2668286C (en) | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| WO2008109057A1 (en) | 2007-03-02 | 2008-09-12 | Dana-Farber Cancer Institute, Inc. | Organic compounds and their uses |
| JP5454943B2 (ja) | 2007-04-12 | 2014-03-26 | ジョイアント ファーマスーティカルズ、インク． | 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体 |
| WO2008128171A2 (en) | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| PE20130150A1 (es) | 2007-04-30 | 2013-02-27 | Genentech Inc | Inhibidores de las iap |
| WO2008144925A1 (en) | 2007-05-30 | 2008-12-04 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| KR20100038108A (ko) | 2007-07-25 | 2010-04-12 | 브리스톨-마이어스 스큅 컴퍼니 | 트리아진 키나제 억제제 |
| EP2058312A1 (en) | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
| PE20110547A1 (es) | 2008-10-29 | 2011-08-04 | Celgene Corp | Compuestos de isoindolina con actividad anticancerigena |
| US20120135089A1 (en) | 2009-03-17 | 2012-05-31 | Stockwell Brent R | E3 ligase inhibitors |
| WO2010141805A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of trpa1 |
| JP2012532929A (ja) | 2009-07-13 | 2012-12-20 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 二機能性のステープリングされたポリペプチドおよびそれらの使用 |
| EP2784076A1 (en) | 2009-10-28 | 2014-10-01 | Joyant Pharmaceuticals, Inc. | Dimeric SMAC mimetics |
| EP2536706B1 (en) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| SG186389A1 (en) | 2010-06-30 | 2013-01-30 | Univ Brandeis | Small-molecule-targeted protein degradation |
| EP2619184B1 (en) | 2010-09-24 | 2018-05-23 | The Regents of the University of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| AU2011338615B2 (en) | 2010-12-07 | 2017-07-27 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| US20140243282A1 (en) | 2010-12-31 | 2014-08-28 | Satish Reddy Kallam | Methods and compositions for designing novel conjugate therapeutics |
| US8889684B2 (en) * | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| KR101911972B1 (ko) * | 2011-02-07 | 2018-10-25 | 플렉시콘 인코퍼레이티드 | 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증 |
| CA2834535A1 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| WO2013071035A1 (en) | 2011-11-09 | 2013-05-16 | Ensemble Therapeutics | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| WO2013071039A1 (en) | 2011-11-09 | 2013-05-16 | Ensemble Therapeutics | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| CN103159736B (zh) * | 2011-12-10 | 2015-05-13 | 通化济达医药有限公司 | 取代的吡唑激酶抑制剂 |
| US9273046B2 (en) * | 2011-12-31 | 2016-03-01 | Beigene, Ltd. | Fused tricyclic compounds as Raf kinase inhibitors |
| WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| CA2861066C (en) * | 2012-01-12 | 2024-01-02 | Yale University | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase |
| US20150141470A1 (en) * | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| US20150119435A1 (en) | 2012-05-11 | 2015-04-30 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| EP2855483B1 (en) | 2012-05-24 | 2017-10-25 | Novartis AG | Pyrrolopyrrolidinone compounds |
| NZ631477A (en) | 2012-05-30 | 2016-12-23 | Hoffmann La Roche | Substituted pyrrolidine-2-carboxamides |
| US9345740B2 (en) | 2012-07-10 | 2016-05-24 | Bristol-Myers Squibb Company | IAP antagonists |
| US9371568B2 (en) | 2012-07-31 | 2016-06-21 | Novartis Ag | Markers associated with human double minute 2 inhibitors |
| WO2014025759A1 (en) | 2012-08-09 | 2014-02-13 | Bristol-Myers Squibb Company | Iap antagonists |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| WO2014047024A1 (en) | 2012-09-18 | 2014-03-27 | Bristol-Myers Squibb Company | Iap antagonists |
| JP6407504B2 (ja) | 2012-09-21 | 2018-10-17 | アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法 |
| US9603889B2 (en) | 2012-10-02 | 2017-03-28 | Bristol-Myers Squibb Company | IAP antagonists |
| TW201428002A (zh) | 2012-11-09 | 2014-07-16 | 必治妥美雅史谷比公司 | 用於抑制細胞凋亡抑制劑之巨環化合物 |
| US9637493B2 (en) | 2012-12-20 | 2017-05-02 | Merck Sharp & Dohme Corp. | Substituted pyrrolopyrimidines as HDM2 inhibitors |
| TW201429969A (zh) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶 |
| EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
| GB201311910D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel Compounds |
| NL2011274C2 (en) | 2013-08-06 | 2015-02-09 | Illumicare Ip B V 51 | Groundbreaking platform technology for specific binding to necrotic cells. |
| CA2902856C (en) | 2013-02-28 | 2021-02-16 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EP3019517A1 (en) | 2013-07-12 | 2016-05-18 | Bristol-Myers Squibb Company | Iap antagonists |
| US20150259288A1 (en) | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| AU2015247817C1 (en) | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| US20160022642A1 (en) | 2014-07-25 | 2016-01-28 | Yale University | Compounds Useful for Promoting Protein Degradation and Methods Using Same |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| GB201504314D0 (en) * | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
| US10730870B2 (en) * | 2015-03-18 | 2020-08-04 | Arvinas Operations, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| HUE054149T2 (hu) | 2015-06-04 | 2021-08-30 | Arvinas Operations Inc | Proteolízis imid-alapú modulátorai és ezekkel kapcsolatos felhasználási eljárások |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017011371A1 (en) | 2015-07-10 | 2017-01-19 | Arvinas, Inc | Mdm2-based modulators of proteolysis and associated methods of use |
| CA2988436A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| WO2017024318A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| AU2016349781A1 (en) * | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
| US11395820B2 (en) | 2016-03-16 | 2022-07-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| EP3445357B1 (en) | 2016-04-22 | 2021-05-26 | Dana-Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| WO2018053354A1 (en) | 2016-09-15 | 2018-03-22 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| WO2018071606A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| IL290809B2 (en) | 2016-11-01 | 2024-01-01 | Arvinas Operations Inc | Tau-protein targeting protacs and associated methods of use |
| CA3042301A1 (en) | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| KR102674902B1 (ko) | 2016-12-01 | 2024-06-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| MX2019007646A (es) | 2016-12-23 | 2019-09-06 | Arvinas Operations Inc | Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso. |
| CN117510491A (zh) * | 2016-12-23 | 2024-02-06 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法 |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| AU2018211975B2 (en) | 2017-01-26 | 2022-05-26 | Arvinas Operations, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
| BR112019015484A2 (pt) | 2017-01-31 | 2020-04-28 | Arvinas Operations Inc | ligantes de cereblon e compostos bifuncionais compreendendo os mesmos |
| EP3580212A4 (en) | 2017-02-08 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | REGULATION OF CHEMERIC ANTIGEN RECEPTORS |
| US10787443B2 (en) | 2017-04-28 | 2020-09-29 | Zamboni Chem Solutions Inc. | RAF-degrading conjugate compounds |
-
2017
- 2017-12-22 CN CN202311248251.7A patent/CN117510491A/zh active Pending
- 2017-12-22 WO PCT/US2017/068322 patent/WO2018119448A1/en not_active Ceased
- 2017-12-22 JP JP2019534245A patent/JP7679173B2/ja active Active
- 2017-12-22 US US15/853,166 patent/US10723717B2/en active Active
- 2017-12-22 EP EP17882647.5A patent/EP3558994A4/en active Pending
- 2017-12-22 IL IL325835A patent/IL325835A/en unknown
- 2017-12-22 KR KR1020197021537A patent/KR102564201B1/ko active Active
- 2017-12-22 IL IL294423A patent/IL294423B2/en unknown
- 2017-12-22 CN CN201780087131.XA patent/CN110741004B/zh active Active
- 2017-12-22 KR KR1020257024694A patent/KR20250117470A/ko active Pending
- 2017-12-22 IL IL304704A patent/IL304704B1/en unknown
- 2017-12-22 KR KR1020237026280A patent/KR102839545B1/ko active Active
- 2017-12-22 CA CA3047784A patent/CA3047784A1/en active Pending
- 2017-12-22 MX MX2019007649A patent/MX2019007649A/es unknown
- 2017-12-22 BR BR112019012878-6A patent/BR112019012878A2/pt active Search and Examination
- 2017-12-22 AU AU2017382436A patent/AU2017382436C1/en active Active
-
2019
- 2019-06-17 IL IL267410A patent/IL267410A/en unknown
- 2019-06-21 MX MX2023009031A patent/MX2023009031A/es unknown
- 2019-07-23 CO CONC2019/0007894A patent/CO2019007894A2/es unknown
-
2021
- 2021-01-08 AU AU2021200099A patent/AU2021200099B2/en active Active
-
2023
- 2023-02-03 JP JP2023015526A patent/JP2023065395A/ja active Pending
-
2024
- 2024-10-16 JP JP2024180795A patent/JP2025016525A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7679173B2 (ja) | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 | |
| JP2020504741A5 (https=) | ||
| KR102642203B1 (ko) | 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법 | |
| US11986531B2 (en) | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | |
| AU2025275145A1 (en) | Cereblon ligands and bifunctional compounds comprising the same | |
| CN119019369A (zh) | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 | |
| JP2020505327A (ja) | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 | |
| JP2020505327A5 (https=) | ||
| JP2020506914A5 (https=) | ||
| BR112017028394A2 (en) | compound, composition, and methods for inducing degradation of a target protein in a cell and for treating a diseased condition or a diseased condition. | |
| RU2830173C2 (ru) | Полициклические соединения и способы целенаправленной деградации полипептидов быстро ускоренной фибросаркомы | |
| US20260115296A1 (en) | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | |
| RU2782458C2 (ru) | Соединения и способы нацеленного расщепления полипептидов быстропрогрессирующей фибросаркомы |